We have described the development and characterization of a panel of reagents, both monoclonal antibodies and recombinant proteins, that should prove useful for further elucidating endosialin/TEM-1 expression and biological function in cells/tissues from healthy and disease states, especially cancer. Here, CD248 is linked to cancer.